Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.55 |
| ▸ | LMNA | P02545 | 4/20 | 0.55 |
| ▸ | TP53 | P04637 | 2/20 | 0.55 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.47 |
| ▸ | KDR | P35968 | 1/20 | 0.47 |
| ▸ | TEK | Q02763 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | RAF1 | P04049 | 6/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.42 |
| ▸ | BRAF | P15056 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4321389 | 0.92 | KDR (0.48) | MAPTLMNATP53EPHB4KDR | |
| SCHEMBL4328514 | 0.91 | KDR (0.49) | MAPTLMNATP53EPHB4KDR | |
| SCHEMBL4321685 | 0.87 | EPHB4 (0.58) | MAPTLMNAEPHB4KDRTEK | |
| SCHEMBL4317796 | 0.84 | EPHB4 (0.56) | MAPTLMNATP53EPHB4KDR | |
| SCHEMBL4330751 | 0.83 | KMT2A (0.48) | MAPTEPHB4CYP1A2CYP2C19MEN1 | |
| SCHEMBL4318407 | 0.83 | KDR (0.51) | MAPTLMNAEPHB4KDRTEK | |
| SCHEMBL4325178 | 0.82 | KMT2A (0.48) | MAPTTP53EPHB4CYP1A2CYP2C19 | |
| SCHEMBL4323351 | 0.82 | KDR (0.51) | MAPTLMNAEPHB4KDRTEK | |
| SCHEMBL4326281 | 0.82 | EPHB4 (0.49) | MAPTLMNAEPHB4KDRTEK | |
| SCHEMBL4329334 | 0.81 | KDR (0.46) | MAPTLMNATP53EPHB4KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1858877-B1 | 1,3 SUBSTITUTED DIARYL UREAS AS MODULATORS OF KINASE ACTIVITY | GILEAD CONNECTICUT INC (US) | 2014-03-12 | — | — | EP | claimed |
| US-7625931-B2 | 1-(5-Chloro-2,4-dimethoxy-phenyl)-3-[3-(2-pyridin-4-yl-imidazol-1-ylmethyl)-phenyl]-urea; treating cancer and diseases characterized by a change in angiogenesis; breast neoplasia, endometrial cancer, colon and neck cancer | CGI PHARMACEUTICALS, INC. (US) | 2009-12-01 | — | — | US | claimed |
| EP-1858877-A1 | 1,3 SUBSTITUTED DIARYL UREAS AS MODULATORS OF KINASE ACTIVITY | CGI Pharmaceuticals, Inc. (US) | 2007-11-28 | — | — | EP | claimed |
| US-20060211738-A1 | Certain substituted diphenyl ureas, as modulators of kinase activity | GILEAD CONNECTICUT, INC. | 2006-09-21 | — | — | US | claimed |
| WO-2006076592-A1 | 1,3 SUBSTITUTED DIARYL UREAS AS MODULATORS OF KINASE ACTIVITY | CGI PHARMACEUTICALS, INC. (US) | 2006-07-20 | — | — | WO | claimed |
| EP-1858877-B1 | 1,3 SUBSTITUTED DIARYL UREAS AS MODULATORS OF KINASE ACTIVITY | GILEAD CONNECTICUT INC (US) | 2014-03-12 | — | — | EP | disclosed |
| EP-1858877-B1 | 1,3 SUBSTITUTED DIARYL UREAS AS MODULATORS OF KINASE ACTIVITY | GILEAD CONNECTICUT INC (US) | 2014-03-12 | — | — | EP | disclosed |
| US-7625931-B2 | 1-(5-Chloro-2,4-dimethoxy-phenyl)-3-[3-(2-pyridin-4-yl-imidazol-1-ylmethyl)-phenyl]-urea; treating cancer and diseases characterized by a change in angiogenesis; breast neoplasia, endometrial cancer, colon and neck cancer | CGI PHARMACEUTICALS, INC. (US) | 2009-12-01 | — | — | US | disclosed |
| US-7625931-B2 | 1-(5-Chloro-2,4-dimethoxy-phenyl)-3-[3-(2-pyridin-4-yl-imidazol-1-ylmethyl)-phenyl]-urea; treating cancer and diseases characterized by a change in angiogenesis; breast neoplasia, endometrial cancer, colon and neck cancer | CGI PHARMACEUTICALS, INC. (US) | 2009-12-01 | — | — | US | disclosed |
| US-7625931-B2 | 1-(5-Chloro-2,4-dimethoxy-phenyl)-3-[3-(2-pyridin-4-yl-imidazol-1-ylmethyl)-phenyl]-urea; treating cancer and diseases characterized by a change in angiogenesis; breast neoplasia, endometrial cancer, colon and neck cancer | CGI PHARMACEUTICALS, INC. (US) | 2009-12-01 | — | — | US | disclosed |
| EP-1858877-A1 | 1,3 SUBSTITUTED DIARYL UREAS AS MODULATORS OF KINASE ACTIVITY | CGI Pharmaceuticals, Inc. (US) | 2007-11-28 | — | — | EP | disclosed |
| US-20060211738-A1 | Certain substituted diphenyl ureas, as modulators of kinase activity | GILEAD CONNECTICUT, INC. | 2006-09-21 | — | — | US | disclosed |
| WO-2006076592-A1 | 1,3 SUBSTITUTED DIARYL UREAS AS MODULATORS OF KINASE ACTIVITY | CGI PHARMACEUTICALS, INC. (US) | 2006-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211738-A1 | Certain substituted diphenyl ureas, as modulators of kinase activity | UCK2, AXL, CHUK | MAPT 1868/4885LMNA 3862/4885TP53 133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.